A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice

by Piers E. M. Patten, Piers E. M. Patten, Gerardo Ferrer, Shih-Shih Chen, Jonathan E. Kolitz, Jonathan E. Kolitz, Kanti R. Rai, Kanti R. Rai, Steven L. Allen, Steven L. Allen, Jacqueline C. Barrientos, Jacqueline C. Barrientos, Nikolaos Ioannou, Alan G. Ramsay, Nicholas Chiorazzi, Nicholas Chiorazzi, Nicholas Chiorazzi
Published 2021-03-01

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

by Marco Montillo, Árpád Illés, Tadeusz Robak, Alexander S. Pristupa, Malgorzata Wach, Miklós Egyed, Julio Delgado, Wojciech Jurczak, Franck Morschhauser, Anna Schuh, Herbert Eradat, Sanatan Shreay, Jacqueline C. Barrientos, Andrew D. Zelenetz
Published 2019-11-01

Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course

by Davide Bagnara, Davide Bagnara, Catherine Tang, Jennifer R. Brown, Siddha Kasar, Stacey Fernandes, Monica Colombo, Stefano Vergani, Andrea N. Mazzarello, Fabio Ghiotto, Fabio Ghiotto, Silvia Bruno, Fortunato Morabito, Fortunato Morabito, Kanti R. Rai, Kanti R. Rai, Jonathan E. Kolitz, Jonathan E. Kolitz, Jacqueline C. Barrientos, Jacqueline C. Barrientos, Steven L. Allen, Steven L. Allen, Franco Fais, Franco Fais, Matthew D. Scharff, Thomas MacCarthy, Nicholas Chiorazzi, Nicholas Chiorazzi
Published 2021-05-01

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

by Steven E. Coutre, Ian W. Flinn, Sven de Vos, Jacqueline C. Barrientos, Marshall T. Schreeder, Nina D. Wagner-Johnson, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Lyndah Dreiling, Yeonhee Kim, Siddhartha Mitra, Kanti Rai, John P. Leonard, Richard R. Furman
Published 2018-06-01